Ardelyx, Inc. (ARDX)

$0.594

+0.00 (+0.70%)
Rating:
Recommendation:
Neutral
Symbol ARDX
Price $0.594
Beta 1.854
Volume Avg. 3.59M
Market Cap 85.892M
Shares () -
52 Week Range 0.49-8.247
1y Target Est -
DCF Unlevered ARDX DCF ->
DCF Levered ARDX LDCF ->
ROE -177.07% Strong Sell
ROA -118.29% Strong Sell
Operating Margin -
Debt / Equity 101.60% Buy
P/E -
P/B 1.21 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest ARDX news


Mr. Michael Raab
Healthcare
Biotechnology
NASDAQ Global Market

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.